What is claimed is:

~~1. A pharmaceutical combination comprising regorafenib and acetylsalicylic acid, or a hydrate,~~ solvate, metabolite or pharmaceutically acceptable salt thereof, or a polymorph thereof.

2. The combination of claim 1 which is a pharmaceutical composition comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof, or a polymorph thereof in one dosage form.

3. The combination of claim 1 which is a combination pack containing the components separate from one another.

4. The combination of claim 1 wherein the components are administered in separate dosage forms simultaneously or sequentially for the treatment of the same disease.

5. The combination of any of claims 1 to 4 for the use as medicament for treating hyper-proliferative disorders.

6. The combination of claim 5 wherein the hyper-proliferative disorders are selected from the group consisting of cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases.

7. The combination of any of claims 5 to 6 wherein the hyper-proliferative disorders are selected from the group consisting of colorectal cancer and gastrointestinal stromal tumors (GIST).

8. The combination of any of claims 1 to 7 administered in a way wherein regorafenib and acetylsalicylic acid are administered daily for the first three weeks and in the fourth week only regorafenib is administered daily.

9. The combination of any of claims 1 to 8 containing regorafenib in an amount of 10 to 1000 ~~mg and acetylsalicylic acid in an amount of 50 to 1000 mg.~~

~~10.~~ 10. A method of treating hyper-proliferative disorders in a subject in need thereof comprising administering effective amounts of regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof, or a polymorph thereof.